DE69823843D1 - Benzimidazolinone, benzoxazolinone, benzopiperazinone, indanone und deren derivate als faktor xa inhibitoren - Google Patents

Benzimidazolinone, benzoxazolinone, benzopiperazinone, indanone und deren derivate als faktor xa inhibitoren

Info

Publication number
DE69823843D1
DE69823843D1 DE69823843T DE69823843T DE69823843D1 DE 69823843 D1 DE69823843 D1 DE 69823843D1 DE 69823843 T DE69823843 T DE 69823843T DE 69823843 T DE69823843 T DE 69823843T DE 69823843 D1 DE69823843 D1 DE 69823843D1
Authority
DE
Germany
Prior art keywords
factor
inhibitors
benzopiperazinone
benzimidazolinone
benzoxazolinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69823843T
Other languages
English (en)
Other versions
DE69823843T2 (de
Inventor
Qi Han
Celia Dominguez
C Amparo
M Park
L Quan
A Rossi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of DE69823843D1 publication Critical patent/DE69823843D1/de
Application granted granted Critical
Publication of DE69823843T2 publication Critical patent/DE69823843T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
DE69823843T 1997-09-09 1998-09-08 Benzimidazolinone, benzoxazolinone, benzopiperazinone, indanone und deren derivate als faktor xa inhibitoren Expired - Lifetime DE69823843T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5828897P 1997-09-09 1997-09-09
US58288P 1997-09-09
PCT/US1998/018729 WO1999012903A1 (en) 1997-09-09 1998-09-08 Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa

Publications (2)

Publication Number Publication Date
DE69823843D1 true DE69823843D1 (de) 2004-06-17
DE69823843T2 DE69823843T2 (de) 2005-05-12

Family

ID=22015876

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69823843T Expired - Lifetime DE69823843T2 (de) 1997-09-09 1998-09-08 Benzimidazolinone, benzoxazolinone, benzopiperazinone, indanone und deren derivate als faktor xa inhibitoren

Country Status (9)

Country Link
US (2) US6207697B1 (de)
EP (1) EP1015429B1 (de)
JP (1) JP2001515887A (de)
AT (1) ATE266636T1 (de)
AU (1) AU9309898A (de)
CA (1) CA2303438A1 (de)
DE (1) DE69823843T2 (de)
ES (1) ES2216309T3 (de)
WO (1) WO1999012903A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2348267A1 (en) * 1998-10-29 2000-05-11 Henry H. Gu Novel inhibitors of impdh enzyme
WO2000071493A2 (en) * 1999-05-24 2000-11-30 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
AU6762400A (en) * 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
RS51449B (sr) * 2001-01-26 2011-04-30 Schering Corporation Kombinacija aktivatora peroksizom proliferator-aktiviranog receptora (ppar) i inhibitora apsorpcije sterola i lečenje vaskularnih indikacija
ATE345793T1 (de) * 2001-09-21 2006-12-15 Schering Corp Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
EP1446134B1 (de) * 2001-11-21 2010-09-22 The Chinese University Of Hong Kong Zusammensetzungen aus organischen extrakten von geum japonicum thunb var. und ihre verwendung
DE10231105A1 (de) 2002-07-10 2004-01-22 Clariant Gmbh Neue Diketopyrrolopyrrolpigmente
CA2507707C (en) 2002-12-03 2011-06-21 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517573C (en) * 2003-03-07 2011-12-06 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7235543B2 (en) * 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ATE418551T1 (de) * 2003-03-07 2009-01-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
PT1664036E (pt) 2003-09-03 2012-02-16 Pfizer Compostos de benzimidazolona que possuem actividade agonística do receptor 5-ht4
EP1719761A4 (de) * 2004-02-23 2007-10-10 Dainippon Sumitomo Pharma Co Neue heterocyclische verbindung
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
EP1758891A2 (de) * 2004-06-15 2007-03-07 Pfizer Japan Inc. Benzimidazoloncarbonsäurederivate
JP4130220B1 (ja) * 2005-02-22 2008-08-06 ファイザー株式会社 ５ｈｔ４受容体アゴニストとしてのオキシインドール誘導体
DK1928454T3 (da) 2005-05-10 2014-11-03 Intermune Inc Pyridonderivater til modulering af stress-aktiveret proteinkinasesystem
JP5174658B2 (ja) * 2005-06-25 2013-04-03 ストライカー・コーポレイション 小型クラッチおよび揺動防止連結ヘッドを有する外科用ハンドピース
US7790726B2 (en) * 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
WO2007084841A2 (en) 2006-01-13 2007-07-26 Wyeth Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors
US7851468B2 (en) * 2006-05-15 2010-12-14 Cephalon, Inc. Substituted pyrazolo[3,4-d]pyrimidines
US20100256147A1 (en) * 2007-04-13 2010-10-07 Hangauer Jr David G Biaryl acetamide derivatives as modulators of the kinase cascade for the treatment of hearing loss, osteoporosis and cell proliferation disorders
US8124605B2 (en) * 2007-07-06 2012-02-28 Kinex Pharmaceuticals, Llc Compositions and methods for modulating a kinase cascade
ES2567283T3 (es) 2008-06-03 2016-04-21 Intermune, Inc. Compuestos y métodos para tratar trastornos inflamatorios y fibróticos
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN109999040A (zh) 2012-08-30 2019-07-12 阿西纳斯公司 蛋白质酪氨酸激酶调节剂
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TWI657085B (zh) 2013-10-04 2019-04-21 英菲尼提製藥股份有限公司 雜環化合物及其用途
JP6701088B2 (ja) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
WO2016104630A1 (ja) * 2014-12-26 2016-06-30 武田薬品工業株式会社 縮合複素環化合物
KR20180058741A (ko) 2015-09-14 2018-06-01 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
EP3830093A1 (de) 2018-07-27 2021-06-09 Biotheryx, Inc. Bifunktionelle verbindungen als cdk-modulatoren
WO2021222150A2 (en) 2020-04-28 2021-11-04 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2626128A1 (de) * 1976-06-11 1977-12-22 Beiersdorf Ag N-substituierte benzimidazolin-2-one und verfahren zu deren herstellung
US4110465A (en) * 1977-11-25 1978-08-29 Eli Lilly And Company 7-amino and 7-alkanoylamino 2-oxo-3-phenylindolines
DE3803775A1 (de) * 1988-02-09 1989-08-17 Boehringer Mannheim Gmbh Neue substituierte lactame, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US5317103A (en) 1991-01-15 1994-05-31 Merck Sharp & Dohme Limited Indole-substituted five-membered heteroaromatic compounds as 5-HT1 agonists
ZA928276B (en) * 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
JPH07509452A (ja) 1992-07-24 1995-10-19 メルク　シヤープ　エンド　ドーム　リミテツド イミダゾール，トリアゾール及びテトラゾール誘導体
SK94393A3 (en) * 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
JP3457694B2 (ja) 1993-02-04 2003-10-20 第一製薬株式会社 インフルエンザ感染予防・治療薬
US5430043A (en) * 1993-08-24 1995-07-04 G. D. Searle & Co. Platelet aggregation inhibitors
US5674894A (en) * 1995-05-15 1997-10-07 G.D. Searle & Co. Amidine derivatives useful as platelet aggregation inhibitors and vasodilators
US5612363A (en) * 1995-06-02 1997-03-18 Berlex Laboratories, Inc. N,N-di(aryl) cyclic urea derivatives as anti-coagulants
ATE267011T1 (de) * 1995-12-21 2004-06-15 Bristol Myers Squibb Pharma Co Isoxazolin, isothiazolin und pyrazolin als faktor xa inhibitoren
TW399051B (en) 1996-01-31 2000-07-21 Ssp Co Ltd A novel benzoazine thiazolidinedione derivative and pharmaceutical composition for reducing blood glucose
ATE228111T1 (de) * 1996-02-22 2002-12-15 Bristol Myers Squibb Pharma Co M-amidinophenyl-analoga als faktor-xa-inhibitoren
US5886191A (en) * 1997-08-18 1999-03-23 Dupont Pharmaceuticals Company Amidinoindoles, amidinoazoles, and analogs thereof
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
ES2216309T3 (es) 2004-10-16
EP1015429B1 (de) 2004-05-12
US20010021775A1 (en) 2001-09-13
US6552042B2 (en) 2003-04-22
AU9309898A (en) 1999-03-29
EP1015429A1 (de) 2000-07-05
CA2303438A1 (en) 1999-03-18
US6207697B1 (en) 2001-03-27
ATE266636T1 (de) 2004-05-15
JP2001515887A (ja) 2001-09-25
DE69823843T2 (de) 2005-05-12
WO1999012903A1 (en) 1999-03-18

Similar Documents

Publication Publication Date Title
ATE266636T1 (de) Benzimidazolinone, benzoxazolinone, benzopiperazinone, indanone und deren derivate als faktor xa inhibitoren
ATE297203T1 (de) Antithrombotische mitteln
ATE405266T1 (de) Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa
ATE272633T1 (de) Aromatische amiden
ATE306261T1 (de) Antithrombosemittel
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
ATE269312T1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
ATE326453T1 (de) Antithrombotische amide
DE69720773T2 (de) SAUERSTOFF ODER SCHWEFEL ENTHALTENDE 5-GLIEDRIGE HETEROAROMATISHE DERIVATIVE ALS FACTOR Xa HEMMER
DE69926806D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
ES2196917T3 (es) Amidas heteroaromaticas como inhibidores del factor xa`.
EA199900591A1 (ru) АЗОТСОДЕРЖАЩИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
TR200102839T2 (tr) LH agonistleri olarak faydalı bisiklik heteroaromatik bileşikler.
SE9904508D0 (sv) New compounds
DK1204650T3 (da) Substituerede 2-arylbenzazol-forbindelser og anvendelse deraf som antitumormidler
ATE495187T1 (de) Dalda-analoge und ihre verwendung
BR0108816A (pt) Derivados de quinolina como antagonistas alfa-2
BR0315777A (pt) Uso de derivados de piperazina como antagonistas ccr1
BR0007864A (pt) Composto, e, uso de um composto
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
DE69915687D1 (de) Heterocyclische amide als inhibitoren von faktor xa
DE60112960D1 (de) Kondensierte pyridoindolderivate
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE

Legal Events

Date Code Title Description
8364 No opposition during term of opposition